The deal was co-led by Forbion Capital Partners (
arGEN-X will use the proceeds to further develop the Company's proprietary, unencumbered SIMPLE Antibody(TM) engine and to continue to build a proprietary pre-clinical antibody product portfolio. arGEN-X's SIMPLE Antibody(TM) platform yields monoclonal antibodies which combine an unparalleled functional diversity against human disease targets with best in class human germline homology. arGEN-X's SIMPLE Antibodies(TM) are generated in vivo, starting from active immunization, and exhibit ultra high starting affinities and potencies without the need for further engineering.
The arGEN-X platform has the potential to rapidly create exciting product candidates both against novel therapeutic targets and against targets where standard antibody approaches fail to generate an optimal lead diversity.
Christina Takke, PhD, Principal at Forbion Capital Partners commented: "We are impressed with the quality of the arGEN-X management team, their solid business approach and outstanding achievements to date. The current financing round will allow arGEN-X to unlock the real value of its technology. Forbion is very pleased to support arGEN-X's future plans in the highly attractive monoclonal antibody space."
Note for the Editor
About arGEN-X - http://www.arGEN-X.com
arGEN-X is a research stage biopharmaceutical company with a broadly applicable, proprietary SIMPLE Antibody(TM) platform. The platform allows arGEN-X to create an unparalleled diversity of in vivo generated antibody leads against a broad range of human disease targets. This superior choice of ultra-high affinity and highly potent leads, having best-in-class human homology, allows for more stringent lead selection criteria, thereby increasing the probability of success later in the drug development path. The Company has validated its monoclonal antibody platform on two human disease targets and has broad patent claims in place covering its technology.
arGEN-X(TM) and SIMPLE Antibody(TM) are deposited trademarks of arGEN-X BV.
SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.
About Forbion Capital Partners - http://www.forbion.com
Forbion Capital Partners is a
About LSP - http://www.lspvc.com
LSP (Life Sciences Partners) is a leading independent European investment
firm, providing financing to private and public life-science companies. Since
the late 1980s, LSP's management has invested in a large number of highly
innovative enterprises, many of which have grown to become leaders of the
global life-science industry. For example, LSP was a founding investor in
Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over
About KBC Private Equity - http://www.kbcpe.be
KBC Private Equity, the private equity company of the KBC Group, provides
development capital to and finances buy-outs of small and medium-sized
companies. KBC Private Equity takes both majority and minority stakes in
companies and contributes financial resources in the form of equity finance
and/or mezzanine finance. Boasting an experienced team of 25 people, KBC
Private Equity has more than 60 active direct investments in portfolio with a
market value in excess of
The Life Sciences division of KBC Private Equity invests in early- to late-stage life-science companies, with a focus on pharmaceutical biotech. Investments include Ablynx, Devgen, Innogenetics, Movetis, and Tibotec-Virco.
About BioGeneration Ventures - http://www.biogenerationventures.com
BioGeneration Ventures invests in seed and early stage Dutch Life Sciences companies. The team of BioGeneration is specialized in creating value from new technologies and the management of start-up companies. BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative (NGI), NWO, the holding of the University of Leiden, and ABN-AMRO Capital.
About Erasmus MC Biomedical Fund - http://www.erasmusmcfund.nl
The Erasmus MC Biomedical Fund is an independent venture capital fund
focusing on early stage companies and (university) spin-outs in the
biotechnology and biomedical field with a presence in the
About Thuja Capital Healthcare Funds - http://www.thujacapital.com
The Thuja Capital Healthcare Fund and Thuja Capital Healthcare Seed Fund
are venture capital funds structured to invest in life sciences innovations
with a focus on therapeutics, diagnostics and medical devices. Whereby the
prime focus of the Seed Fund is on privately held early-stage life sciences
companies located in
For further information, please contact: Citigate Dewe Rogerson David Dible, Mark Swallow T: +44-207-282-2949 / 2948 E: David.Dible@citigatedr.co.uk arGEN-X Tim Van Hauwermeiren, MSc, eMBA Chief Executive Officer T: +31-6-122-85-257 E: tim.vh@arGEN-X.com